Search
Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)
Study characteristics:
- 2,400 patients > 70 years of age with family history of Alzheimer's disease, asymptomatic at start of study
- randomized trial
Treatment
- celecoxib 200 mg BID
- naproxen 220 mg BID
- placebo
Results: (preliminary)
1) increased risk of cardiovascular & cerebrovascular events in naproxen group compared with placebo
2) no increase in cardiovascular or cerebrovascular events with celecoxib vs placebo
General
clinical trial
References
- Prescriber's Letter 12(2): 2005
Detail-Document#: 210202
(subscription needed) http://www.prescribersletter.com
- [No authors listed]
Cardiovascular and Cerebrovascular Events in the Randomized,
Controlled Alzheimer's Disease Anti-Inflammatory Prevention
Trial (ADAPT).
PLoS Clin Trials. 2006 Nov 17;1(7):e33 [Epub ahead of print]
PMID: 17111043
- Nissen SE.
ADAPT: The Wrong Way to Stop a Clinical Trial.
PLoS Clin Trials. 2006 Nov 17;1(7):e35 [Epub ahead of print]
PMID: 17111045